---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-115765"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:20:25.693415+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA

## Summary
- Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).
- TuHURA securityholders own ~97.15% (or 94.55% after CVR shares).
- 1-for-35 reverse stock split pre-merger; common stock now trades under HURA on Nasdaq.
- CVRs issued to former Kintara holders; up to ~1.54M shares payable if REM-001 CMBC study milestone met by Dec 31, 2025.
- Combined company focuses on TuHURA's personalized cancer vaccine IFx-2.0; Phase 3 trial in MCC planned for Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-115765
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 1.01, 9.01, 5.02, 2.02, 3.03, 5.01, 5.03, 5.06, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024115765/0000950170-24-115765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024115765/hura-20241018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-115765
- JSON: https://secwatch.observer/filing/0000950170-24-115765.json
- Plain text: https://secwatch.observer/filing/0000950170-24-115765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.